Cardiac Biomarkers Testing Market Set to Surge to $28.1 Billion by 2030 at a 10.9% CAGR

As of 2020, the global cardiac biomarkers testing market was valued at approximately $9.77 billion. Projections indicate that this figure will reach $28.10 billion by 2030, reflecting a CAGR of 10.9% from 2021 to 2030. The global cardiac biomarkers testing market has experienced significant growth in recent years, driven by advancements in diagnostic technologies, an increase in cardiovascular diseases (CVDs), and a growing emphasis on early detection and prevention. Cardiac biomarkers are protein molecules released into the bloodstream after heart damage or stress, serving as critical indicators for various heart conditions. This report delves into the market's current landscape, growth factors, segmentation, and key players.

Read More Here: https://www.alliedmarketresearch.com/cardiac-biomarkers-testing-market

Cardiac Biomarkers Testing Market Growth Factors

Several factors contribute to the robust expansion of the cardiac biomarkers testing market:

1. Rising Prevalence of Cardiovascular Diseases: The increasing incidence of CVDs globally has heightened the demand for effective diagnostic tools. Cardiac biomarkers testing plays a pivotal role in the early detection and management of these conditions.

2. Advancements in Diagnostic Technologies: Continuous innovations have led to the development of more accurate and rapid testing methods, enhancing the reliability of cardiac biomarker assays.

3. Growing Geriatric Population: An aging global population is more susceptible to heart-related ailments, thereby increasing the need for cardiac biomarkers testing.

4. Government and Private Funding: Increased investments in research and development by governmental and private entities have accelerated the discovery of novel biomarkers and the improvement of existing testing methodologies.

Get Sample PDF Copy: https://www.alliedmarketresearch.com/request-sample/5284

Cardiac Biomarkers Testing Market Segmentation

The cardiac biomarkers testing market is segmented based on biomarker type, application, location of testing, and region.

By Biomarker Type:

- Troponins (T and I): These biomarkers held the largest market share in 2020, owing to their high specificity and sensitivity in detecting myocardial infarction.

- Creatine Kinase-MB (CK-MB): Expected to grow at a CAGR of 13.0% during the forecast period, CK-MB is utilized for its effectiveness in diagnosing heart attacks.

- Myoglobin: Serves as an early marker for muscle injury, including cardiac damage.

- Natriuretic Peptides (BNP and NT-proBNP): Used primarily in the diagnosis and management of congestive heart failure.

- Ischemia Modified Albumin (IMA): Employed in detecting ischemic conditions in the heart.

By Application:

- Myocardial Infarction: Accounted for the largest share in 2020, driven by the high prevalence of heart attacks globally.

- Congestive Heart Failure: This segment is anticipated to grow at a CAGR of 12.2%, attributed to the rising incidence of heart failure cases.

- Acute Coronary Syndrome: Encompasses conditions associated with sudden, reduced blood flow to the heart.

- Atherosclerosis: Involves the buildup of fats and cholesterol in artery walls, leading to cardiovascular complications.

By Location of Testing:

- Laboratory Testing: Held the largest share in 2020, due to the comprehensive analysis capabilities and accuracy of laboratory settings.

- Point-of-Care Testing: Expected to witness significant growth, offering rapid results and convenience, especially in emergency scenarios.

By Region:

- North America: Dominated the market in 2020, attributed to high healthcare expenditure, advanced infrastructure, and the presence of major industry players.

- Europe: Holds a significant market share, supported by a well-established healthcare system and increasing awareness of early cardiac diagnostics.

- Asia-Pacific: Projected to register the highest CAGR of 12.5% during the forecast period, driven by investments in healthcare infrastructure and a rising burden of CVDs.

- LAMEA (Latin America, Middle East, and Africa): Offers potential growth opportunities with improving healthcare access and increasing awareness of cardiac health.

Key Players in the Cardiac Biomarkers Testing Market

The cardiac biomarkers testing market features several prominent companies:

- Roche Diagnostics
- Abbott Laboratories
- Siemens Healthcare
- Alere Inc.
- Becton, Dickinson and Company
- Bio-Rad Laboratories
- bioMérieux
- Randox Laboratories
- Beckman Coulter
- Thermo Fisher Scientific

These companies are actively involved in research, development, and distribution of cardiac biomarker tests, contributing to market expansion.

The cardiac biomarkers testing market is poised for substantial growth, driven by the increasing prevalence of cardiovascular diseases, technological advancements, and a focus on early diagnosis. As research progresses and new biomarkers are identified, healthcare providers will be better equipped to manage and treat heart conditions, ultimately improving patient outcomes.

Procure Complete Report: https://www.alliedmarketresearch.com/checkout-final/ad0c81460e0c22089086480133113cc3?utm_source=Nilesh.Musale

Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.

Contact Us:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.